Free Trial

Bone Biologics (BBLG) Competitors

Bone Biologics logo
$2.42 +0.02 (+0.83%)
Closing price 04:00 PM Eastern
Extended Trading
$2.38 -0.04 (-1.49%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BBLG vs. CHEK, BTCY, SINT, POAI, MHUA, XAIR, INBS, FEMY, TNON, and LYRA

Should you be buying Bone Biologics stock or one of its competitors? The main competitors of Bone Biologics include Check-Cap (CHEK), Biotricity (BTCY), Sintx Technologies (SINT), Predictive Oncology (POAI), Meihua International Medical Technologies (MHUA), Beyond Air (XAIR), Intelligent Bio Solutions (INBS), Femasys (FEMY), Tenon Medical (TNON), and Lyra Therapeutics (LYRA). These companies are all part of the "medical equipment" industry.

Bone Biologics vs. Its Competitors

Check-Cap (NASDAQ:CHEK) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by company insiders. Comparatively, 7.5% of Bone Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Bone Biologics had 1 more articles in the media than Check-Cap. MarketBeat recorded 2 mentions for Bone Biologics and 1 mentions for Check-Cap. Check-Cap's average media sentiment score of 1.91 beat Bone Biologics' score of 0.84 indicating that Check-Cap is being referred to more favorably in the media.

Company Overall Sentiment
Check-Cap Very Positive
Bone Biologics Positive

Check-Cap has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

Check-Cap's return on equity of 0.00% beat Bone Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
Check-CapN/A N/A N/A
Bone Biologics N/A -100.58%-93.31%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A-$25.15M-$3.00-0.78
Bone BiologicsN/AN/A-$4.11MN/AN/A

Summary

Bone Biologics beats Check-Cap on 5 of the 8 factors compared between the two stocks.

Get Bone Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BBLG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BBLG vs. The Competition

MetricBone BiologicsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.31M$3.12B$5.70B$10.39B
Dividend YieldN/A2.42%5.78%4.70%
P/E RatioN/A21.6975.6026.38
Price / SalesN/A437.29536.29234.17
Price / CashN/A43.2725.6730.68
Price / Book0.299.7212.826.40
Net Income-$4.11M-$52.86M$3.29B$276.69M
7 Day Performance13.08%1.75%1.12%-0.28%
1 Month Performance12.56%8.64%4.54%6.69%
1 Year Performance-82.84%19.19%68.00%27.61%

Bone Biologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BBLG
Bone Biologics
1.2932 of 5 stars
$2.42
+0.8%
N/A-83.0%$4.31MN/A0.002News Coverage
Analyst Upgrade
CHEK
Check-Cap
N/A$2.24
-8.6%
N/A+88.2%$14.34MN/A-0.7580Positive News
BTCY
Biotricity
N/A$0.57
-6.8%
N/A+136.0%$14.27M$12.06M-0.5340Gap Down
SINT
Sintx Technologies
2.0332 of 5 stars
$4.88
+3.6%
$25.00
+412.3%
+32.4%$12.99M$2.89M-0.1040Analyst Upgrade
Gap Down
POAI
Predictive Oncology
0.8553 of 5 stars
$1.16
-0.9%
N/A-1.4%$12.74M$1.62M-0.3830News Coverage
Stock Split
Gap Up
Trading Halted
High Trading Volume
MHUA
Meihua International Medical Technologies
1.8052 of 5 stars
$0.40
+2.1%
N/A-64.0%$12.51M$96.91M0.00620Positive News
XAIR
Beyond Air
4.415 of 5 stars
$2.31
-1.7%
$11.00
+376.2%
-66.2%$12.28M$3.70M-0.1970
INBS
Intelligent Bio Solutions
0.8518 of 5 stars
$1.32
-1.9%
N/A-38.5%$12.21M$3.05M-0.6410Positive News
Analyst Downgrade
FEMY
Femasys
2.735 of 5 stars
$0.34
-4.7%
$7.33
+2,029.3%
-67.9%$11.77M$1.89M-0.4030
TNON
Tenon Medical
1.9868 of 5 stars
$1.22
-0.8%
$5.50
+350.8%
-74.3%$10.92M$2.95M-0.048
LYRA
Lyra Therapeutics
3.3436 of 5 stars
$6.64
+3.4%
$100.00
+1,406.0%
-51.3%$10.56M$1.53M-0.2350Positive News

Related Companies and Tools


This page (NASDAQ:BBLG) was last updated on 9/29/2025 by MarketBeat.com Staff
From Our Partners